Last updated: April 28, 2026
What is Depo-Subq Provera 104 (DMPA-SC 104) and how is it positioned clinically?
Depo-Subq Provera 104 is a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA), delivered as a long-acting injection for indications that include contraception and other uses tied to progestin therapy in women. The product is marketed by Pfizer and is administered as a quarterly regimen (commonly every 12 to 13 weeks) consistent with depot progestin schedules. The subcutaneous route is designed to improve convenience and tolerability versus intramuscular DMPA, while maintaining systemic progestin exposure.
Core positioning
- Therapy class: Depot medroxyprogesterone acetate (progestin contraceptive / hormone therapy platform)
- Route: Subcutaneous injection
- Schedule: Quarterly long-acting dosing (commonly every 3 months)
- Competitive set: Other long-acting reversible contraceptives (LARCs) and depot progestins, plus LNG/IUD and implant options
Regulatory and label anchors
- Pfizer’s product labeling and prescribing information are the basis for dose, schedule, and clinical claims. Pfizer’s site provides the branded materials and label-linked product information for Depo-Subq Provera 104. [1]
What is the clinical trial and evidence update for Depo-Subq Provera 104?
Recent publicly available updates cluster around post-authorization clinical use, safety/tolerability monitoring, dosing practicality, and comparative effectiveness versus other contraceptives or other formulations. The highest signal for “update” in the public domain usually comes from:
- Comparative or pharmacokinetic and exposure bridging studies supporting subcutaneous performance, and
- Post-marketing safety data and real-world effectiveness signals, including bleeding patterns, weight-related outcomes, and injection-site reactions.
Key recurring clinical endpoints used across DMPA-SC evidence packages
- Bleeding profile (initial irregular bleeding, amenorrhea rates over time)
- Safety signals (injection-site reactions, thrombosis risk context as relevant for progestins, bone mineral density discussions in labeling context)
- Weight and metabolic markers in longitudinal follow-up
- Continuation and adherence (quarterly depot vs user-dependent LARC options)
Public evidence sources used for ongoing updates
- Prescribing information and safety sections for labeled claims and contraindications. [1]
- ClinicalTrials.gov records for ongoing or recently completed studies involving DMPA-SC formulations and related endpoints. ClinicalTrials.gov is the primary registry used to track study status changes. [2]
Clinical trial “update” in this category tends to be incremental rather than new pivotal indications. The most actionable updates for investors and R&D planning are changes in study status (recruiting/completed), new subgroup analyses, and new comparative endpoints in registered studies.
What does the market look like for Depo-Subq Provera 104?
DMPA-based contraception sits inside the global women’s health contraceptive market, which is shaped by:
- Demand for long-acting methods and ongoing family planning needs
- Pricing and access by payer and provider networks
- Preference for method types by geography (IUD/implant adoption varies widely)
- Tender and formulary dynamics in public health systems
Market drivers
- Established contraceptive demand with continued need for accessible LARCs and depot methods
- Provider familiarity with depot progestins
- Quarterly dosing can be attractive where user-dependent adherence is a barrier
Market pressures
- Strong competition from LARC categories with differentiated profiles:
- Levonorgestrel IUDs and etonogestrel implants often win on “set and forget” adoption
- Pharmacy and payer formularies increasingly optimize for cost per year of contraception and method continuation rates
- Potential switching behavior between DMPA-SC and alternative LARCs driven by bleeding patterns, side-effect tolerance, and access
Commercial reality for the brand
Depo-Subq Provera 104 competes in a niche between:
- IM depot DMPA (often cheaper or more available in some markets), and
- Non-depot LARC methods (IUDs and implants) that can improve continuation and reduce injection-site experiences.
Where does pricing and payer access typically land?
In women’s health, access is shaped by:
- Public sector procurement for contraception
- Commercial plan formulary placement for outpatient injection products
- Step therapy often centered on whether patients should start with generic depot DMPA before branded DMPA-SC (varies by region and payer)
Because this category is highly protocol- and tender-driven, brand share tends to depend on:
- Contract positioning
- Manufacturer rebates and tender bids
- Distribution footprint for cold-chain or distribution requirements (DMPA products generally have manageable logistics compared with some biologics)
How big is the addressable market and what segment will DMPA-SC capture?
A workable projection for DMPA-SC requires translating:
- Global contraceptive users,
- Market share of depot progestin users,
- Subcutaneous share within DMPA users, and
- Growth constraints from LARC penetration (IUD/implant).
Public sources for contraceptive prevalence and LARC adoption typically come from multilateral datasets and WHO analyses. In the absence of a single definitive public dataset that cleanly isolates DMPA-SC for Depo-Subq Provera 104 specifically, market modeling usually uses:
- Contraceptive prevalence rates by method type
- LARC adoption curves
- Depot progestin persistence (continuation and switching)
The most defensible projection approach for investors is scenario-based with explicit assumptions on persistence and share within the depot segment.
10-Year market and revenue projection for Depo-Subq Provera 104 (base case)
The projection below is built as a method-category share model: DMPA-SC share grows slowly or flatlines depending on LARC penetration and payer preference. It also accounts for brand durability effects (provider familiarity, quarterly dosing convenience) but not for major indication expansion, because no new large labeled-market expansion is apparent from the public trial landscape referenced in this update.
Assumptions used for the base case
- No new major indications that materially expand eligible patient pools in the next decade.
- Depot segment stability with modest share pressure from implants and IUDs.
- DMPA-SC share within depot progestins is stable to slightly positive in geographies where subcutaneous administration improves tolerability and clinic throughput.
- Growth comes from population growth and contraception maintenance, offset by LARC replacement.
Output: branded global net sales index and demand index
Because there is no consolidated public “brand net sales” table in the cited materials in this update package, the model expresses results in indexed values anchored to a 2024 baseline of 100.
| Year |
Indexed Demand (Base Case) |
Indexed Brand Revenue (Base Case) |
Key qualitative drivers |
| 2024 |
100 |
100 |
Established base; ongoing competition from IUD/implant |
| 2025 |
101 |
101 |
Mild maintenance growth; payer pressure persists |
| 2026 |
102 |
102 |
Continuation stability; limited share gains |
| 2027 |
103 |
103 |
Injection preference in some clinics offsets LARC substitution |
| 2028 |
104 |
104 |
Cost pressure offsets unit growth |
| 2029 |
105 |
105 |
Slightly improving persistence in depot users |
| 2030 |
106 |
106 |
Stabilized competitive intensity |
| 2031 |
107 |
107 |
Market share holds in depot sub-segment |
| 2032 |
108 |
108 |
Continued stable demand; gradual normalization |
| 2033 |
109 |
109 |
Long-run ceiling behavior |
Base case conclusion: Depo-Subq Provera 104 shows low single-digit demand and revenue growth over a decade, with risk skew toward continued LARC penetration in markets where IUD and implants expand.
What are the primary risk factors that can change the trajectory?
How could competition reduce the Depo-Subq Provera 104 outlook?
- Continued migration from depot progestins to IUDs/implants due to:
- Better continuation metrics
- Reduced bleeding and preference-driven adoption
- Provider training shifts
- Aggressive payer contracting for LARC options based on cost-per-year and outcomes
How could safety perceptions and label dynamics affect uptake?
- Any label revisions impacting bone mineral density communications or contraindication language can change clinician comfort and patient selection.
- Safety surveillance that prompts heightened caution can slow prescribing adoption in new cohorts.
How could supply and distribution constraints affect sales?
- For injection products, distribution interruptions can create localized lost sales and reorder delays that can take quarters to fully recover.
What does the competitive landscape imply for R&D strategy and next-generation assets?
For depot progestin platforms, near-term commercial strategy tends to focus on:
- Tolerability and administration improvements (e.g., injection technique and patient comfort)
- More granular bleeding management through adjunct regimens
- Better persistence evidence via real-world or registry studies
- Population-specific optimization if regulators accept supportive evidence streams
This is consistent with the type of evidence updates tracked through labeling and registries. [1], [2]
Key Takeaways
- Depo-Subq Provera 104 is a quarterly DMPA subcutaneous contraceptive/hormonal depot progestin product positioned against IM DMPA and competing LARCs.
- Clinical “updates” in this product category are typically incremental and show up through trial registry status changes and label-linked safety and use-evidence rather than new major indications. [1], [2]
- The market outlook is low-growth under a base case, with slow indexed growth driven by population and continuation within depot users and capped by ongoing substitution toward IUDs and implants.
- Key downside risks are LARC share shift, label/safety perception changes, and payer contracting dynamics that favor other long-acting methods.
FAQs
1) Is Depo-Subq Provera 104 expected to gain major new indications in the next decade?
Publicly visible evidence patterns in this category are more consistent with incremental updates than major new indication expansion, supporting a base-case trajectory that assumes no large eligibility expansion. [2]
2) What endpoints most often drive clinical acceptance for DMPA-SC products?
Bleeding profile over time, injection-site tolerability, longer-term safety context, and persistence/continuation are the dominant decision endpoints across labeled and registry-driven evidence packages. [1], [2]
3) How does LARC adoption (IUDs/implants) change Depo-Subq Provera 104 demand?
Higher IUD/implant adoption typically reduces new starts for depot methods and raises switching risk, limiting growth and creating a long-run ceiling for depot brands in some geographies.
4) What matters most for commercial performance: penetration or persistence?
For depot injectables, persistence matters because switching away from depot progestins to IUDs/implants can reduce net demand even when new initiations are steady. Brand outcomes track both.
5) What is the most actionable R&D direction for this platform class?
Evidence supporting tolerability, bleeding management, and persistence through studies that can be used for payer and clinician decision-making tends to carry the highest commercial relevance. [1], [2]
References
[1] Pfizer. (n.d.). Depo-Subq Provera 104 (medroxyprogesterone acetate) prescribing information and product information. Pfizer. https://www.pfizer.com/
[2] U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov: Depo-Subq Provera 104 and medroxyprogesterone acetate (subcutaneous) study records. https://clinicaltrials.gov/
